



Life Sciences Company with an Evolving Portfolio of Novel Psychedelic and Anti-Viral Drugs

September 2021

BETRF : OTCBB

BETR : CSE

DISCLAIMER

This presentation may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. BetterLife Pharmaceuticals Inc. (“BetterLife” or the “Company”) considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, include, amongst other factors, those related to the timing or successful completion of the Company’s development plans including, but not limited to synthesis of its compounds, obtaining regulatory approval, success of pre-clinical and clinical studies. Forward-looking information is based upon a number of assumptions and estimates of management at the date the statements are made. Risk factors include among other things BetterLife’s ability to raise capital to complete its plans and fund its studies and assumptions are inherently subject to significant economic, social, political, competitive and regulatory and other uncertainties. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company’s ongoing continuous disclosure and other filings found on SEDAR at www.sedar.com.


Highlights



MENTAL HEALTH

Second Generation, Non-Hallucinogenic Psychedelic Drugs

- Patient friendly answer to mental health's unmet needs
- No scheduled drug restrictions and faster development



ANTI-INFECTION

Novel Anti-Viral Drugs for Treatment and Potential Prevention of Pandemics

- Effective for the treatment of Covid-19 and its variants
- Potential prevention of pandemics



MANAGEMENT

- Extensive experience in all aspects of drug development
- Big pharma expertise matched with determination of small biotech
- Public company and capital markets management expertise

Three Compelling & Differentiated Assets

Second Generation (non-hallucinogenic) Psychedelics

TD-0148A: 2-bromo-LSD (oral)

- Indication: Major depressive disorder (MDD)
- IND filing projected Q1 2022
- IP: Two manufacturing patents that eliminate controlled substance regulatory controls (issued); Method of use (pending)


TD-010: DHH-B (oral)

- Indication: Benzodiazepine dependency
- IND filing projected Q1 2022
- IP: Method of use (pending)

Novel Anti-virals

AP-003: Inhaled interferon alpha-2b (IFN α 2b)

- Indication: Early stage Covid-19 infection
- IND filing projected Dec 2021
- IP: Composition and formulation (pending).



5

TD-0148A

Non-Hallucinogenic LSD

2-bromo-LSD

Potential Treatment of Major Depressive Disorders
and Other Neuro-Psychiatric Disorders



TD-0148A


TD-0148A: 2-bromo-LSD – Background

BOL-148 (2-bromo-LSD)


- BOL-148 is not a controlled substance, but due to its synthesis from LSD, its manufacturing is regulated as for LSD
- Was originally synthesized by Albert Hofmann, the chemist who invented LSD
- BOL-148 shown to be non-hallucinogenic in humans (trials in 50s – 60s)
- BOL-148 shown to be effective against cluster headaches in a trial in 2010

TD-0148A (BetterLife's proprietary 2-bromo-LSD)


- There are also no controlled substance intermediates at any stage in TD-0148A synthesis: No residual LSD (unlike BOL-148)
- TD-0148A manufacturing, final product and use are totally free of controlled substance regulations



Lysergic acid diethylamide
(LSD)



2-bromo-LSD



The TD-0148A Advantage: Benefits of LSD without the hallucinations + Not a controlled substance

The Achilles Heel of Psychedelics ¹

Two main issues which arise from their “hallucinogenic” properties:

1. Administration must be performed in special clinics with close monitoring by a trained therapist(s) in a four-step treatment model; and
2. They are controlled substances making the manufacturing, distribution, and eventual patient access and administration a highly regulated and difficult process.

Use of psychedelics as treatment drugs for the greater population is impractical: restrictions, high overhead costs, and patient access.

	TD-0148A	PSILOCYBIN	LSD	MDMA
Schedule 1 Drug	NO	Yes	Yes	Yes
Multiple Formal Human Studies	Yes	Yes	Yes	Yes
Hallucinogenic Effects	NO	Yes	Yes	Low/No
List 1 Precursors	NO	Yes	Yes	Yes
UN Convention Illicit Drug	NO	Yes	Yes	Yes
Patient Self-Administered	YES	No	No	No
Regulatory Hurdle	LOW	High	High	High

**TD-0148 IP:
Proprietary Synthesis (Issued) and Method
of Use (Pending)**

Issued IP: Synthesis

BetterLife synthesis patent for 2-Bromo-LSD eliminates regulatory hurdles. TD-0148A is an unregulated, unscheduled molecule, with no legal barriers to surmount.


Filed IP (pending): Method of Use

Filing covers treatment of MDD including TRD, migraines, PTSD and other neuro-psychiatric disorders



TD-0148A: A Significant Market Opportunity

Depression and Other Neuro-Psychiatric Disorders Market Share, by Indication ¹



- The global depression drugs market reached US\$ 12.41 Billion in 2019. ²
- According to the WHO, depression is one of the leading causes of disability and is currently prevalent in nearly 265 million people across the globe (with an estimate that only about 35% cases are reported). ³
- This global depression market is projected to reach near US\$ 25 Billion by 2030. ⁴
- Increase in fear, worry and social anxiety driven by negative socio-economic, geo-political and biological-environmental (eg COVID, climate change, etc) factors, are fueling the growth of this market. ⁵

1. Transparency Market Research Report 2020: Depression Market Drugs.

2. IMARC Report 2020: Depression Drugs Market 2020: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

3. <https://www.who.int/news-room/fact-sheets/detail/depression>

4. Transparency Market Research Report 2020: Depression Market Drugs.

5. IMARC Report 2020: Depression Drugs Market 2020: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

TD-0148A Development Plan Projections

10

Drug	Delivery	Indication	Current Status	IND	Phase 1	Phase 2
TD-0148A	Oral (capsules)	Major Depressive Disorder	Preclinical IND-enabling studies	Filing projected Q1 2022	Ph 1 in Healthy Subjects Start Q1 2022	Ph 2 in MDD Start Q4 2022
	Oral (capsules)	Other Neuro-Psychiatric Disorders				TBD after IND filing

TD-010

Dihydrohonokiol-B (DHH-B)


Potential Treatment of Anxiety and other Neuro-Psychiatric Disorders



TD-010: Dihydrohonokiol (DHH-B) – The Background


Honokiol (the parent of DHH-B)

- Magnolia bark extracts have been used in traditional Chinese medicines for centuries as anxiolytic (anti-anxiety medication)
- Several animal studies on safety and anxiolytic efficacy of honokiol/magnolia bark extract have been published
- Magnolia bark extract/honokiol is sold as a nutraceutical



TD-010 (BetterLife's proprietary DHH-B)

- Also shown in animal studies **not to be addictive like benzodiazepines**
- Anecdotal oral reports from drug rehabilitation clinics claim oral DHH-B is a highly effective anxiolytic and an effective treatment for benzodiazepine dependency
- TD-010 is DHH-B formulated in BetterLife's patented formulation⁷ to overcome its poor bioavailability



13
**TD-010 IP:
Proprietary Formulation & Method of Use
(Pending)**

Filed IP (pending): Formulation

BetterLife's patented formulation improves bioavailability. Formulations covered include oral capsules, tablets, sub-lingual etc delivery.

Filed IP (pending): Method of Use

Filing covers treatment of anxiety, benzodiazepine dependency, insomnia, etc.



Patent Pending, Filed: 2019-08-06
International Patent: Priority Filing

Int'l Filing Date: 2020-06-08

TD-010: A Significant Market Opportunity



- Benzodiazepines market was valued at US\$ 3.48 Billion in 2019 and is projected to reach US\$ 4.15 Billion by 2027, growing at a CAGR of 2.25% from 2020 to 2027.
- Rise in prevalence of anxiety and seizures is a major driver of the global benzodiazepine drugs market. Current lifestyle and urban life have made peoples' lives more stressful, which leads to mental disorders such as depression, anxiety, panic, and maniac conditions.
- “Although these drugs are legally manufactured and prescribed by doctors, they are acutely addictive.”
- Majority of benzodiazepine users are at risk of dependency, and therefore potential candidates for TD-010.

TD-010 Development Plan Projections

15

Drug	Delivery	Indication	Current Status	IND	Phase 1	Phase 2
TD-010	Oral (capsules)	Benzodiazepine Dependency	Preclinical IND-enabling studies	Filing projected Q1 2022	Ph 1 in healthy subjects <u>OR</u> Ph 1-2 in patients Start Q1 2022	
	Oral (capsules)	Other Neuro-Psychiatric Disorders ³				TBD after IND filing

16

AP-003

Interferon alpha-2b (IFN α 2b)
Inhalation

Potential Treatment & Prophylaxis
of COVID-19





AP-003: Unique Market Position and Opportunity

- AP-003 is being developed as a novel interferon alpha-2b (IFN α 2b) inhalation formulation
- U of Texas, showed evidence of a direct anti-viral effect of interferon alpha against novel coronavirus in vitro. The study demonstrated around 10,000 fold reduction in the quantity of virus that was pretreated with interferon alpha 48 hours earlier.
- IFN α 2b has been used to treat COVID-19 in China²
- AP-003 may be used to treat patients **early** after COVID-19 or its variants' infection which may prevent the progression to severe disease and need for hospitalization³
- Positive clinical trials may potentially position AP-003 as an initial treatment for COVID – 19 or its variants and other respiratory viruses (MERs, SARs)
- AP-003 has potential to be used as prophylaxis/prevention – huge market expansion opportunity

1. Subject to successful outcome of clinical trials and obtaining market authorization

2. Dong et al, 2020; Lu, 2020; Shen & Yang, 2020; Zhou et al, 2020

AP-003 Patent Pending Application Covers Composition, Formulation and Treatment

◦ Composition

- AP-003 is manufactured from a novel IFNa2b recombinant clone. The IFNa2b is “isoform” free.

◦ Formulation

- Patent pending proprietary AP-003 formulation improves stability of the IFNa2b and is adapted to inhalation delivery
- Additional formulations also are covered

◦ Potential Treatment & Prevention/ Prophylaxis

- Altum’s AP-003 patent application covers potential treatment of COVID-19 (and all other respiratory tract viral infections)
- Altum’s AP-003 patent application also describes potential prevention/prophylaxis against COVID-19 (and all other respiratory tract viral infections)




AP-003 Development Plan Projections

19

Drug	Delivery	Indication	Manufacturing / Pre-Clinical / IND enabling studies	IND	Phase 1	Phase 2
AP-003	Inhalation (nebulizer)	Treatment Early Stage Covid-19 ¹	+ PoC Chilean Ph 1-2 Study (discussed below)	Filing projected Dec 2021		Ph 2 in US Start Q1 2022

Leadership




Leadership Team

Management

Advisors



Ahmad Doroudian, PhD Founder, CEO
25+ years experience in finance, M&A,
Founder of Merus Labs (NASDAQ: MSLI)




Jeff Fellows, Regulatory Affairs



Hooshmand Sheshbaradaran, PhD, Chief Operating Officer
30+ years senior pharma executive
drug development, operations, licensing and M&A




Thomas P. Laughren, M.D. Psychiatry



Scott Rudge, PhD, Head of CMC
20+ years in CMC development




Eleanor Fish, PhD, Immunology, Infectious Diseases




Moira Ong, CA, Chief Financial Officer
20+ years, financial and corporate reporting



Argel Aguilar-Valles, PhD, Neuroscience, Depression



Abdi Ghaffari, PhD, Head of Preclinical Research
15+ years, Pre-Clinical R&D



Warner K. Huh, MD, Gynecologist, Cervical Neoplasia



David Lin, PhD, MBA Regulatory,
Formerly at FDA CDER



Share Capital

	Issued and Outstanding	Exercise Price
Common shares	84,321,672	N/A
Restricted and performance stock units	42,500	N/A
Stock options	1,540,000 440,000 195,000 143,750	C\$0.63 – C\$0.77 C\$1.33 – C\$1.80 C\$2.40 – C\$2.60 C\$3.09 – C\$4.00
Warrants	23,316,250 6,386,298 452,595 1,118,304 804,851	C\$0.50 C\$0.60 C\$1.21 – C\$1.88 C\$2.30 - C\$3.00 C\$6.00
Compensation Units	519,053 1,967,750	C\$0.50 C\$0.40

23

Thank You



BetterLife Pharma

Contact:

CEO: Ahmad Doroudian, Ph.D
BetterLife Pharma Inc.
300 - 1275 West 6th Avenue
Vancouver, BC V6H 1A6
Canada.

Tel: 604 221-0595

Ahmad.Doroudian@blifepharma.com